Literature DB >> 3297373

Chemical xenogenization of experimental tumors.

P Puccetti, L Romani, M C Fioretti.   

Abstract

Chemical xenogenization occurs when experimental tumors, treated in vivo or in vitro with selected chemicals, become immunogenic, i.e., able to induce a strong rejection response, immunological in nature, in the histocompatible hosts. Unlike modifications induced by haptens, changes in tumor cell immunogenicity associated with chemical xenogenization are heritable as a result of drug interference with the genetic code. Drugs endowed with potent mutagenic activity are known to be powerful xenogenizing agents, and their mechanism of action is traditionally regarded as involving changes in DNA nucleotide sequence. Triazene and nitrosoguanidine derivatives are among the best known examples of this type of compound, and a large body of information has been accumulated over the years regarding the immunogenic properties of the tumor variants obtained following treatment with those xenogenizing agents. The present paper reviews this information, and also discusses the therapeutic implications of xenogenization in experimental systems of tumor immunotherapy. Xenogenization of murine tumors has also been obtained by means of chemicals devoid of mutagenic activity but capable of affecting gene transcriptional activity. The characteristics of this 'new' type of xenogenization are also reviewed and compared to those of triazene xenogenization.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3297373     DOI: 10.1007/BF00052845

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  77 in total

1.  Effects of mutagens on the immunogenicity of tumor cells: comparison of cell surface changes induced by 5-azacytidine and N-methyl-N'-nitro-N-nitrosoguanidine.

Authors:  P Altevogt
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

2.  Induction of tumor cell rejection in the low responsive YAC-lymphoma strain A host combination by immunization with somatic cell hybrids.

Authors:  G Klein; E Klein
Journal:  Eur J Cancer       Date:  1979-04       Impact factor: 9.162

3.  Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide.

Authors:  E Bonmassar; A Bonmassar; S Vadlamudi; A Goldin
Journal:  Cancer Res       Date:  1972-07       Impact factor: 12.701

4.  Active specific immunotherapy of minimal residual tumor: excision plus neuraminidase-treated tumor cells.

Authors:  A Rios; R L Simmons
Journal:  Int J Cancer       Date:  1974-01-15       Impact factor: 7.396

5.  Induction of non-transplantable mutant clones from an ascites tumor.

Authors:  K Koyama; K Ishii
Journal:  Gan       Date:  1969-08

6.  Modification of tumor regression by immunologic means.

Authors:  E Mihich
Journal:  Cancer Res       Date:  1969-12       Impact factor: 12.701

7.  Immunity to lymphoid tumors in syngeneic mice by immunization with mitomycin C-treated cells.

Authors:  E Benjamini; S Fong; C Erickson; C Y Leung; D Rennick; R J Scibienski
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

8.  Growth and rejection patterns of murine lymphoma cells antigenically altered following drug treatment in vivo.

Authors:  C Riccardi; M C Fioretti; A Giampietri; P Puccetti; A Goldin
Journal:  Transplantation       Date:  1978-02       Impact factor: 4.939

9.  Adoptive immunotherapy of intracerebral murine lymphomas: role of different lymphoid populations.

Authors:  L Romani; B Nardelli; R Bianchi; P Puccetti; M Mage; M C Fioretti
Journal:  Int J Cancer       Date:  1985-05-15       Impact factor: 7.396

10.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.

Authors:  T Boon; J Van Snick; A Van Pel; C Uyttenhove; M Marchand
Journal:  J Exp Med       Date:  1980-11-01       Impact factor: 14.307

View more
  9 in total

1.  Lack of correlation between DNA-methylating activity and appearance of the immunogenic phenotype in clones of a murine lymphoma treated with mutagens.

Authors:  P Fuschiotti; M C Fioretti; L Romani; P Puccetti
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Changes in the tumorigenic and metastatic properties of murine melanoma cells treated with a triazene derivative.

Authors:  M Allegrucci; P Fuschiotti; P Puccetti; L Romani; M C Fioretti
Journal:  Clin Exp Metastasis       Date:  1989 May-Jun       Impact factor: 5.150

3.  Regression mechanisms of mouse fibrosarcoma cells after in vitro exposure to quercetin: diminution of tumorigenicity with a corresponding decrease in the production of prostaglandin E2.

Authors:  F Okada; M Hosokawa; J Hasegawa; M Ishikawa; I Chiba; Y Nakamura; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  O6-methylguanine-DNA methyltransferase activity and induction of novel immunogenicity in murine tumor cells treated with methylating agents.

Authors:  R Bianchi; L Citti; R Beghetti; L Romani; M D'Incalci; P Puccetti; M C Fioretti
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Effects of two pyridinalalkyliminerhodium(I) complexes in mice bearing MCa mammary carcinoma.

Authors:  G Sava; S Zorzet; S Pacor; G Mestroni; G Zassinovich
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Cell-mediated immunity to chemically xenogenized tumors. I. Inhibition by specific antisera and H-2 association of the novel antigens.

Authors:  L Romani; U Grohmann; F Fazioli; P Puccetti; M G Mage; M C Fioretti
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Effects of prolonged treatment with decarbazine on tumor metastatic potential in mice bearing Lewis lung carcinoma.

Authors:  S Zorzet; L Perissin; V Rapozzi; S Pacor; T Giraldi
Journal:  Clin Exp Metastasis       Date:  1995-03       Impact factor: 5.150

8.  Immunotherapy of malignancy by in vivo gene transfer into tumors.

Authors:  G E Plautz; Z Y Yang; B Y Wu; X Gao; L Huang; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

Review 9.  Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.

Authors:  Ornella Franzese; Francesco Torino; Maria Pia Fuggetta; Angelo Aquino; Mario Roselli; Enzo Bonmassar; Anna Giuliani; Stefania D'Atri
Journal:  Oncotarget       Date:  2017-06-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.